Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
NCT01312311
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
51
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Cancer
Interventions
DRUG:
Docetaxel, Cisplatin
Sponsor
Samsung Medical Center